Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Gritstone Oncology Inc Market Cap
From what 4 stock analysts predict, the share price for Gritstone Oncology Inc (GRTS) might increase by 2400% in the next year. This is based on a 12-month average estimation for GRTS. Price targets go from $0.5 to $3. The majority of stock analysts believe GRTS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Gritstone Oncology Inc has a total of 4 Wall St Analyst ratings. There are 3 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Gritstone Oncology Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GRTS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mayank Mamtani B. Riley Securities | Neutral | $1 | Downgrade | Oct 2, 2024 |
| Catherine Novack Jones Trading | Hold | Downgrade | Oct 2, 2024 | |
| Roy Buchanan JMP Securities | Market Perform | Downgrade | Oct 1, 2024 | |
| Sean Lee HC Wainwright & Co. | Neutral | $0.5 | Downgrade | Oct 1, 2024 |
| Sean Lee HC Wainwright & Co. | Buy | $4 | Reiterates | Aug 15, 2024 |
| Sean Lee HC Wainwright & Co. | Buy | $4 | Reiterates | Aug 5, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $5 | Reiterates | Aug 5, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $5 | Reiterates | Jun 14, 2024 |
| Mayank Mamtani B. Riley Securities | Buy | $3 | Reiterates | May 24, 2024 |
| Sean Lee HC Wainwright & Co. | Buy | $4 | Maintains | May 13, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $5 | Maintains | Apr 2, 2024 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 6, 2024 |
| Roy Buchanan JMP Securities | Market Outperform | $4 | Initiates | Feb 28, 2024 |
| Edward Tenthoff Piper Sandler | Overweight | $7 | Maintains | Sep 28, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 10, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Reiterates | May 15, 2023 |
| Mayank Mamtani B. Riley Securities | Buy | $8 | Initiates | Mar 28, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 14, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Maintains | Feb 15, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $7 | Maintains | Nov 7, 2022 |
When did it IPO
2018
Staff Count
231
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.
Market Cap
$7.3M
In 2023, GRTS generated $1.3M in revenue, which was a decrease of -85.64% from the previous year. This can be seen as a signal that GRTS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 15 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - A class action lawsuit has been filed against Gritstone bio, Inc. (NASDAQ:GRTS) for alleged securities violations. Affected investors should contact the Schall Law Firm by August 6, 2024.
Why It Matters - A class action lawsuit against Gritstone bio for securities violations could lead to financial penalties or settlements, impacting stock value and investor sentiment.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Preliminary Phase 2 data indicate GRANITE's personalized neoantigen vaccine may benefit metastatic microsatellite-stable colorectal cancer. Mature PFS data is anticipated by Q3 2024.
Why It Matters - Positive Phase 2 data for GRANITE suggests potential market opportunity in colorectal cancer, addressing unmet needs, which could boost the company's valuation and investor sentiment.
Tue, 13 Aug 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Gritstone bio Inc. (GRTS) reported a quarterly loss of $0.16 per share, better than the estimated loss of $0.26 and an improvement from a loss of $0.31 per share a year ago.
Why It Matters - Gritstone bio's smaller-than-expected loss indicates improved performance and potential for recovery, which may boost investor confidence and affect stock valuation positively.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Levi & Korsinsky, LLP has announced a class action securities lawsuit against Gritstone bio, Inc. (NASDAQ: GRTS), affecting investors in the company.
Why It Matters - The class action lawsuit against Gritstone may indicate potential legal risks and financial liabilities, affecting stock performance and investor sentiment.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Gritstone bio, Inc. (NASDAQ: GRTS) shareholders are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment related to a class period.
Why It Matters - The notice indicates potential legal action against Gritstone Bio, which could impact the stock's stability and shareholder confidence, influencing trading decisions and price movement.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - The Gross Law Firm is notifying Gritstone bio, Inc. (NASDAQ: GRTS) shareholders to contact them about potential lead plaintiff appointments for a class action.
Why It Matters - The notice indicates potential legal issues for Gritstone Bio, which could impact its stock price and shareholder confidence, prompting investors to reassess their positions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
